Sage Therapeutics (NASDAQ:SAGE) announced a significant amendment to its 2016 Inducement Equity Plan.

As of April 16, 2024, the board of directors approved a change that will reduce the number of shares reserved for issuance under the plan to 428,074 shares and declared that no future awards would be granted post this date.

This strategic adjustment aims to refine the company's equity compensation framework, ensuring alignment with its long-term objectives and shareholder interests.